BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33563755)

  • 1. CD20 as a gatekeeper of the resting state of human B cells.
    Kläsener K; Jellusova J; Andrieux G; Salzer U; Böhler C; Steiner SN; Albinus JB; Cavallari M; Süß B; Voll RE; Boerries M; Wollscheid B; Reth M
    Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33563755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.
    Kneissl S; Zhou Q; Schwenkert M; Cosset FL; Verhoeyen E; Buchholz CJ
    PLoS One; 2013; 8(11):e79047. PubMed ID: 24244415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
    Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
    Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective calcium signaling and disrupted CD20-B-cell receptor dissociation in patients with common variable immunodeficiency disorders.
    van de Ven AA; Compeer EB; Bloem AC; van de Corput L; van Gijn M; van Montfrans JM; Boes M
    J Allergy Clin Immunol; 2012 Mar; 129(3):755-761.e7. PubMed ID: 22130422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.
    Polyak MJ; Li H; Shariat N; Deans JP
    J Biol Chem; 2008 Jul; 283(27):18545-52. PubMed ID: 18474602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin.
    Benoit NE; Wade WF
    Immunopharmacology; 1996 Nov; 35(2):129-39. PubMed ID: 8956976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2.
    Deans JP; Schieven GL; Shu GL; Valentine MA; Gilliland LA; Aruffo A; Clark EA; Ledbetter JA
    J Immunol; 1993 Nov; 151(9):4494-504. PubMed ID: 7691952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas.
    Adem J; Eray M; Eeva J; Nuutinen U; Pelkonen J
    Mol Immunol; 2017 Aug; 88():135-137. PubMed ID: 28644972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.
    Walshe CA; Beers SA; French RR; Chan CH; Johnson PW; Packham GK; Glennie MJ; Cragg MS
    J Biol Chem; 2008 Jun; 283(25):16971-84. PubMed ID: 18426802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts.
    Petrie RJ; Deans JP
    J Immunol; 2002 Sep; 169(6):2886-91. PubMed ID: 12218101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
    Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
    J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C.
    Valentine MA; Meier KE; Rossie S; Clark EA
    J Biol Chem; 1989 Jul; 264(19):11282-7. PubMed ID: 2472394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role of lipid rafts in CD20 activity?
    Janas E; Priest R; Malhotra R
    Biochem Soc Symp; 2005; (72):165-75. PubMed ID: 15649140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
    Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
    Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
    Front Immunol; 2020; 11():609941. PubMed ID: 33505398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
    Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA
    Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells.
    Camponeschi A; Kläsener K; Sundell T; Lundqvist C; Manna PT; Ayoubzadeh N; Sundqvist M; Thorarinsdottir K; Gatto M; Visentini M; Önnheim K; Aranburu A; Forsman H; Ekwall O; Fogelstrand L; Gjertsson I; Reth M; Mårtensson IL
    J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35819358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis.
    Sjöberg E; Frödin M; Lövrot J; Mezheyeuski A; Johansson M; Harmenberg U; Egevad L; Sandström P; Östman A
    Br J Cancer; 2018 Oct; 119(7):840-846. PubMed ID: 30293996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.